Related Experiment Video
Updated: Sep 24, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Immune phenotype and prognosis in chronic B-lymphocytic leukaemia and leukaemic immunocytoma
Insights
This study on chronic lymphocytic leukemia (CLL) and immunocytoma (IC) found differences in immunoglobulin and T cell markers. Prognosis varied by immunoglobulin phenotype and T cell levels, highlighting distinct biological features.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Distinguishing between chronic lymphocytic leukemia (CLL) and immunocytoma (IC) is crucial for patient management.
- Cell surface immunoglobulin and T cell profiles may offer insights into the distinct biology of these B-cell malignancies.
Purpose of the Study:
- To investigate differences in immunoglobulin (Ig) heavy and light chain phenotypes and T cell content between CLL and IC.
- To evaluate the prognostic significance of these markers in patients with CLL and IC.
Main Methods:
- Analysis of 59 patients diagnosed with B-lymphocytic malignancy (29 CLL, 30 IC) using the Kiel classification.
- Cell surface Ig staining for heavy (mu, gamma) and light (kappa, lambda) chains.
- Flow cytometry to determine T cell percentages in peripheral blood lymphocytes.
Main Results:
- Immunoglobulin isotypes differed significantly: gamma phenotype exclusive to IC (p<0.02), lambda phenotype more frequent in CLL (p<0.04).
- IC patients exhibited higher T cell counts than CLL patients (p<0.002).
- Prognostic impact of kappa vs. lambda phenotype varied by diagnosis; mu phenotype associated with poorer prognosis in IC.
Conclusions:
- Distinct immunoglobulin and T cell profiles differentiate CLL and IC.
- Prognostic implications of Ig phenotype and T cell numbers vary between CLL and IC, suggesting different disease behaviors.
- Further research into these markers could refine diagnostic and prognostic strategies for B-cell malignancies.
Abstract:
Fifty-nine patients with a leukaemic B-lymphocytic malignancy ("CLL") were studied. According to the Kiel classification, 29 patients had chronic lymphocytic leukaemia (CLL) and 30 had immunocytoma (IC). Cell surface immunoglobulin staining showed mu heavy chain phenotype in 14 patients, mu in 35, gamma in 7; in cells from 3 patients the staining was too weak to permit identification. The light chain phenotype was kappa in 39 patients, lambda in 17, and unidentified in 3. The immunoglobulin isotypes differed between the diagnoses. The gamma chain phenotype was found only in IC patients (p less than 0.02), and more CLL than IC patients showed a lambda chain phenotype (p less than 0.04). Blood lymphocytes from IC patients contained more T cells than CLL cell samples (p less than 0.002). No prognostic difference was found between the CLL and IC group. Compared to the lambda phenotype, the kappa phenotype was associated with a poorer prognosis in the IC group, but with a better prognosis in the CLL group. IC patients with mu phenotype had a poorer prognosis than those with gamma phenotype. Low relative T cell numbers were associated with a poor survival (p less than 0.01).
